ADARx Pharmaceuticals has named Donald Fong, MD, its new Chief Medical Officer (CMO). Fong joins after serving in the same post at BioCryst Pharmaceuticals. Duties of ADARx CMO As a late-stage biotechnology company developing next-generation RNA therapeutics, ADARx is enlisting Fong to lead advancement of its clinical-stage pipeline. This includes Phase II and III clinical trials in areas like genetic, cardiovascular, thrombosis, central nervous system, and metabolic diseases. In May...